Keyphrases
Genetic Ancestry
100%
Dose Reduction
100%
Odds Ratio
75%
Disease-free Survival
75%
Taxane-induced Peripheral Neuropathy
75%
Congestive Heart Failure
50%
Clinically Significant
50%
Induced Hypertension
50%
Paclitaxel
50%
Bevacizumab
50%
Hazard Ratio
25%
African American
25%
Invasive Disease
25%
United States
25%
Triple-negative Breast Cancer
25%
Efficacy Endpoint
25%
African Ancestry
25%
European Ancestry
25%
Breast Cancer
25%
Racial Disparities
25%
Risk-benefit Ratio
25%
Estrogen Receptor-positive
25%
Patients with Breast Cancer
25%
Breast Cancer Treatment
25%
Cancer Clinical Trials
25%
Breast Cancer Outcomes
25%
Anthracyclines
25%
Induced Toxicity
25%
P-12
25%
Adjuvant Trials
25%
Adjuvant Breast Cancer
25%
Medicine and Dentistry
Drug Dose Reduction
100%
Electrocorticography
100%
Odds Ratio
75%
Disease Free Survival
75%
Breast Cancer
75%
Peripheral Neuropathy
75%
Congestive Heart Failure
50%
Paclitaxel
50%
Bevacizumab
50%
Hazard Ratio
25%
Estrogen Receptor
25%
Racial Disparity
25%
Triple Negative Breast Cancer
25%
Anthracycline
25%
Breast Cancer Chemotherapy
25%
Nursing and Health Professions
Drug Dose Reduction
100%
Breast Cancer
100%
Electrocorticography
100%
Odds Ratio
75%
Disease Free Survival
75%
Peripheral Neuropathy
75%
Congestive Heart Failure
50%
Paclitaxel
50%
Bevacizumab
50%
Hazard Ratio
25%
Cancer Chemotherapy
25%
Estrogen Receptor
25%
Anthracycline
25%
Triple Negative Breast Cancer
25%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Disease Free Survival
75%
Taxane
75%
Peripheral Neuropathy
75%
Congestive Heart Failure
50%
Paclitaxel
50%
Bevacizumab
50%
Estrogen Receptor
25%
Triple Negative Breast Cancer
25%
Cancer Chemotherapy
25%
Anthracycline
25%
Biochemistry, Genetics and Molecular Biology
Genetics
100%
Drug Dose Reduction
100%
Electrocorticography
100%
Disease Free Survival
75%
Bevacizumab
50%
Estrogen Receptor
25%
Anthracycline
25%